Shell Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 24-12-2024
- Paid Up Capital ₹ 6.08 M
as on 24-12-2024
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.99 Cr
as on 24-12-2024
- Revenue -48.67%
(FY 2023)
- Profit -29.32%
(FY 2023)
- Ebitda -50.42%
(FY 2023)
- Net Worth 5.65%
(FY 2023)
- Total Assets -23.02%
(FY 2023)
About Shell Lifesciences
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 6.08 M.
The company currently has active open charges totaling ₹16.99 Cr.
Kiran Thakkar and Rajkumar Jaiswal serve as directors at the Company.
- CIN/LLPIN
U51496MH2007PTC173957
- Company No.
173957
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Shell Lifesciences Private Limited offer?
Shell Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Animal Medicines & Health Care, Veterinary Medicines, Common Disease Medicines, Steroid.
Who are the key members and board of directors at Shell Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Thakkar  | Director | 01-Sep-2009 | Current |
| Rajkumar Jaiswal | Additional Director | 10-Jul-2024 | Current |
Financial Performance of Shell Lifesciences.
Shell Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48.67% decrease. The company also saw a substantial fall in profitability, with a 29.32% decrease in profit. The company's net worth moved up by a moderate rise of 5.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shell Lifesciences?
In 2023, Shell Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jul 2020 | ₹2.02 Cr | Open |
Others Creation Date: 31 Jan 2018 | ₹7.50 M | Open |
Others Creation Date: 21 Dec 2017 | ₹5.50 M | Open |
How Many Employees Work at Shell Lifesciences?
Unlock and access historical data on people associated with Shell Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shell Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shell Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
